skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpoints |
54 |
6. Filter based on genotype QC (FinnGen only) |
51 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L80-L99
- Name in latin
- Perturbationes eliminationis transepidermalis
Similar endpoints
↥List of similar endpoints to
Transepidermal elimination disorders
based on the number of shared cases.
Similar with more cases:
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 466 | 280 | 178 |
| Only index persons | 395 | 249 | 146 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 56.95 | 57.00 | 56.49 |
| Only index persons | 55.30 | 55.34 | 55.24 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 51 | 32 | 19 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 56.70 | 55.07 | 59.45 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 54
- Matched controls
- 540
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L87.0
ICD-10 Finland
Keratosis follicularis et parafollicularis in cutem penetrans [Kyrle]
+∞
26.2
23
*
L87.1
ICD-10 Finland
Reactive perforating collagenosis
+∞
16.5
15
*
A46
ICD-10 Finland
Erysipelas
9.6
14.2
22
36
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
8.6
12.9
22
40
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
8.0
12.6
24
49
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
150.9
11.9
12
*
J01FF01
ATC
clindamycin; systemic
7.1
11.9
33
98
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
15.2
10.8
18
17
TPH07
NOMESCO Finland
Cathetrisation of artery
7.4
10.2
19
37
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.0
9.7
19
39
TPH04
NOMESCO Finland
Cathetrisation of vein
6.0
9.5
25
68
SPAT1262
SPAT
Handing over of treatment supplies
6.3
9.1
20
46
N03AX16
ATC
[U] pregabalin
5.4
8.7
28
90
Z3229
NOMESCO Finland
Other healthcare associate professional
8.9
8.6
19
31
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.9
8.4
40
176
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
9.8
8.3
17
24
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
22.5
8.0
11
6
L04AX01
ATC
azathioprine; systemic
16.7
7.8
12
9
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.0
7.8
25
79
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.9
7.8
28
97
WX002
NOMESCO Finland
Sedation and analgesia
5.2
7.7
22
63
J01MA02
ATC
ciprofloxacin; systemic
5.0
7.5
36
155
L87.2
ICD-10 Finland
Elastosis perforans serpiginosa
+∞
7.5
7
*
L87.9
ICD-10 Finland
Transepidermal elimination disorder, unspecified
+∞
7.5
7
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
24.0
7.4
10
5
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
5.6
7.2
17
41
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
4.6
7.1
30
116
WX704
NOMESCO Finland
Intubation
11.0
7.0
13
15
N18.8
ICD-10 Finland
Other chronic renal failure
26.4
6.9
9
*
D07AC13
ATC
mometasone; topical
4.6
6.9
25
86
N02AX02
ATC
tramadol; systemic, rectal
4.6
6.8
36
164
A02BC01
ATC
omeprazole; systemic
4.5
6.8
25
87
C03CA01
ATC
furosemide; systemic
4.4
6.7
27
100
L84
ICD-10 Finland
Corns and callosities
17.1
6.7
10
7
WX872
NOMESCO Finland
Intensive care
13.4
6.6
11
10
Z49.1
ICD-10 Finland
Extracorporeal dialysis
78.8
6.6
7
*
WX892
NOMESCO Finland
Monitored bed care
8.6
6.6
14
21
D07AC01
ATC
betamethasone; topical
4.3
6.5
31
130
A12AA04
ATC
calcium carbonate; oral
30.7
6.4
8
*
TK800
NOMESCO Finland
Hemodialysis
30.7
6.4
8
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
9.1
6.4
13
18
P01BA02
ATC
hydroxychloroquine; oral
8.2
6.4
14
22
L87.8
ICD-10 Finland
Other transepidermal elimination disorders
+∞
6.4
6
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
7.5
6.0
14
24
J02AC01
ATC
fluconazole; systemic
4.1
6.0
33
150
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
40
166
6.44
9.33
5.7
2.8
157.63
114.85
ug/l
0.76
40
149
21
53
5.85
8.58
2.3
1.7
—
—
—
0
0
21
53
5.85
8.58
8.0
2.5
25.54
18.87
%
0.54
14
45
18
43
5.78
7.72
1.9
3.6
0.20
0.21
g/l
0.30
18
38
26
87
4.83
7.51
7.2
3.0
32.00
104.29
ng/l
0.63
19
66
20
54
5.29
7.47
2.9
1.5
—
—
—
0
0
23
70
4.98
7.46
2.7
1.9
—
—
—
0
0
43
215
5.91
7.38
22.8
10.0
1.21
1.22
mmol/l
0.69
37
190
26
96
4.29
6.45
1.5
1.1
1.91
2.84
u/ml
—
8
26
12
18
8.23
5.63
11.2
9.4
26.19
26.22
mmol/l
0.01
12
18
15
32
6.07
5.53
9.8
2.8
2.58
3.14
mmol/l
0.19
15
26
15
35
5.52
5.14
9.7
2.7
6.00
6.03
kpa
0.04
15
35
35
193
3.31
4.28
21.9
11.8
1.19
1.30
inr
—
10
58
11
24
5.47
4.01
9.9
3.2
5.15
4.55
kpa
0.30
11
24
13
37
4.29
3.73
2.3
1.4
—
—
—
0
0
9
17
6.12
3.69
9.4
2.8
26.26
24.97
mmol/l
—
9
17
48
350
4.33
3.69
18.7
8.2
96.77
81.97
u/l
1.02
48
330
6
6
11.03
3.59
1.3
1.2
—
—
—
0
0
31
177
2.76
3.28
2.5
1.9
99.38
102.82
pmol/l
0.15
17
77
33
198
2.71
3.12
4.5
2.9
—
—
—
0
0
8
17
5.32
3.05
7.5
2.9
1.63
1.05
%
—
8
17
5
6
9.01
2.80
3.8
1.0
23.54
27.22
mmol/l
—
5
6
8
19
4.75
2.80
8.1
2.5
24.52
25.42
mmol/l
—
8
19
6
11
5.98
2.62
2.0
1.7
4.90
4.65
g/l
—
6
11
40
287
2.52
2.30
9.1
3.2
74.05
58.59
u/l
0.45
40
262
7
19
4.07
2.23
11.3
3.4
61.37
53.77
%
—
7
19
5
10
5.38
2.12
1.8
1.1
—
—
—
0
0
8
26
3.43
2.11
2.3
1.4
—
—
—
0
0
18
95
2.34
2.07
1.8
1.6
23.71
19.95
nmol/l
0.54
18
77
8
28
3.17
1.95
1.1
1.3
—
—
—
0
0
6
17
3.83
1.89
2.5
1.6
1.07
1.19
g/l
—
6
17
6
17
3.83
1.89
2.5
1.6
0.19
0.22
g/l
—
6
17
24
149
2.10
1.84
5.2
3.1
—
—
—
0
0
13
62
2.44
1.83
1.5
1.4
—
—
—
0
0
12
55
2.52
1.83
18.9
9.1
104.17
103.98
mmol/l
0.06
12
55
18
100
2.20
1.81
3.4
2.6
—
—
—
0
0
5
13
4.12
1.75
3.2
1.5
—
—
—
0
0
16
87
2.19
1.68
2.1
1.7
497.88
478.27
pmol/l
0.10
16
74
5
14
3.82
1.65
1.8
1.4
259.00
241.71
%
—
5
14
36
267
2.04
1.64
3.9
3.2
—
—
—
0
0
5
15
3.56
1.56
1.4
1.4
90.80
92.53
%
—
5
15
6
22
2.94
1.48
12.0
13.6
24.10
24.82
mmol/l
—
6
22
5
16
3.33
1.47
1.0
1.0
—
—
—
0
0
5
16
3.33
1.47
1.0
1.2
—
—
—
0
0
45
380
2.10
1.25
59.4
17.2
15.11
15.17
%
0.03
45
372
5
19
2.79
1.24
1.2
2.0
—
—
—
0
0
15
89
1.95
1.24
1.3
1.3
57.70
17.67
iu/ml
—
6
29
9
45
2.20
1.12
8.2
3.2
—
—
—
0
0
5
21
2.52
1.11
1.8
2.4
—
—
—
0
0
27
206
1.62
0.92
8.6
5.1
0.00
0.00
estimate
—
7
34
12
74
1.80
0.87
3.7
2.7
0.69
0.72
e6/l
—
7
41
11
67
1.81
0.82
3.9
2.9
0.83
4.55
e6/l
—
6
34
21
154
1.60
0.82
6.4
3.8
—
—
—
0
0
6
33
1.92
0.82
25.0
10.0
0.93
0.67
%
—
6
33
6
33
1.92
0.82
25.2
10.0
1.02
1.65
%
—
6
33
27
212
1.55
0.78
6.1
3.7
0.00
0.00
estimate
—
8
38
27
213
1.54
0.76
6.2
3.7
0.00
0.00
estimate
—
7
35
22
170
1.50
0.66
5.8
3.5
36.42
36.67
ng/l
0.01
14
114
5
30
1.73
0.63
1.2
1.8
—
—
—
0
0
12
87
1.49
0.47
1.4
1.3
12.42
11.87
u/ml
—
6
37
5
33
1.57
0.42
1.2
2.0
—
—
—
0
0
9
69
1.36
0.40
1.1
1.6
—
—
—
0
0
47
446
1.41
0.25
5.4
4.6
6.69
6.04
mmol/l
1.03
47
410
13
107
1.28
0.24
7.6
4.0
0.00
0.00
estimate
—
6
36
0
11
0.00
0.21
0.0
1.6
—
210.55
—
0
11
0
11
0.00
0.21
0.0
4.5
—
23.73
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
45.14
—
0
14
7
82
0.83
0.07
3.0
3.8
—
23.06
—
0
36
12
112
1.09
0.03
3.0
4.3
0.79
1.66
ug/l
3.58
12
98
0
8
0.00
0.00
0.0
5.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
6.35
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_TRANSEPIDERMELIMINATION and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_TRANSEPIDERMELIMINATION | 1.881 [1.35, 2.62] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.06 |
During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 259 females with L12_TRANSEPIDERMELIMINATION died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_TRANSEPIDERMELIMINATION | 2.845 [1.63, 4.95] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 149 males with L12_TRANSEPIDERMELIMINATION died.
Mortality risk
Mortality risk for people of age
years, who have L12_TRANSEPIDERMELIMINATION.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.202% | 0.466% |
| 5 | 0.896% | 2.788% |
| 10 | 2.435% | 7.127% |
| 15 | 4.718% | 13.85% |
| 20 | 8.183% | 22.8% |
Relationships between endpoints
↥Index endpoint: L12_TRANSEPIDERMELIMINATION – Transepidermal elimination disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data